Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate

Miller, Joe; Tarter, TH

doi:10.2147/cia.s4102

Cited by 32 publications

(13 citation statements)

References 17 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BPH itself does not increase the probability of prostate cancer but these two conditions may occur at the same time. It is also associated with lower urinary tract symptoms (LUTC) such as increased urinary frequency and urgency, nocturia, difficulties with initiating urination, feeling of insufficient bladder emptying, weak and/or interrupted urine stream (Miller & Tarter, 2009). BPH occurs mostly in men after 50 years of age, but it does not occur in men, whose testicles were surgically removed before puberty, indicating that age and hormones are important factors in developing the disorder (Berry et al , 1984; Wang et al , 2014).…”

Section: Prostate and Prostate Cancermentioning

confidence: 99%

Can glycoprofiling be helpful in detecting prostate cancer?

Belický

Tkac

2015

Chemical Papers

View full text Add to dashboard Cite

Glycans are chains of carbohydrates attached to proteins (glycoproteins and proteoglycans) or lipids (glycolipids). Glycosylation is a posttranslational modification and glycans have a wide range of functions in a human body including involvement in oncological diseases. Change in a glycan structure cannot only indicate presence of a pathological process, but more importantly in some cases also its stage. Thus, a glycan analysis has a potential to be an effective and reliable tool in cancer diagnostics. Lectins are proteins responsible for natural biorecognition of glycans, even carbohydrate moieties still attached to proteins or whole cells can be recognized by lectins, what makes them an ideal candidate for designing label-free biosensors for glycan analysis. In this review we would like to summarize evidence that glycoprofiling of biomarkers by lectin-based biosensors can be really helpful in detecting prostate cancer.

show abstract

Section: Prostate and Prostate Cancermentioning

confidence: 99%

Can glycoprofiling be helpful in detecting prostate cancer?

Belický

Tkac

2015

Chemical Papers

View full text Add to dashboard Cite

show abstract

“…However, excessive production of DHT is the cause of major androgen- related disorders such as prostate cancer, acne, female hirsutism, and BPH. [ 1 ] Therefore, inhibitors of androgen action by 5α-reductase is a logical treatment of 5α-reductase activity disorder, that is, BPH. These agents suppress the DHT concentration by blocking the enzyme, resulting in shrinkage in the size of prostate, increased peak urinary flow rates, and ultimately providing relief from the symptoms related to the static mechanical obstruction caused by BPH.…”

Section: Androgen Deprivation Therapymentioning

confidence: 99%

“…BPH clinically manifest as lower urinary tract symptoms (LUTS) consisting of irritative (urgency, frequency, nocturia) and obstructive symptoms (hesitancy, a weak and interrupted urinary stream, straining to initiate urination, a sensation of incomplete bladder emptying). [ 1 ] Prolonged obstructions may eventually lead to acute urinary retention (AUR), recurrent urinary tract infection (UTI), hematuria, bladder calculi, and renal insufficiency. [ 2 ] The prevalence of LUTS due to BPH increases with increasing age.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Benign prostatic hyperplasia: An overview of existing treatment

Dhingra

Bhagwat²

2011

Indian J Pharmacol

View full text Add to dashboard Cite

Benign prostatic hyperplasia (BPH) is the most common condition in aging men, associated with lower urinary tract symptoms (LUTS). A better understanding of the prostate physiology, function, and pathogenesis has led to the development of promising agents, useful in the management of LUTS in men. The specific approach used to treat BPH depends upon number of factors like age, prostrate size, weight, prostate-specific antigen level, and severity of the symptoms. 5α-reductase inhibitors decrease the production of dihydrotestosterone within the prostate, which results in decreased prostate volume, increased peak urinary flow rate, improvement of symptoms, decreased risk of acute urinary retention, and need for surgical intervention. α1-adrenergic receptor (α1-AR) antagonists decrease LUTS and increase urinary flow rates in men with symptomatic BPH, but do not reduce the long-term risk of urinary retention or need for surgical intervention. Clinical efficacy of either 5α-reductase inhibitor or α1-AR antagonist has been further improved by using combination therapy; however, long-term outcomes are still awaited. Many more potential new therapies are under development that may improve the treatment of BPH. This article gives a brief account of rationale and efficacy of different treatment options presently available in the management of BPH.

show abstract

“…The combination product is used for the treatment of moderate to severe symptomatic Benign Prostatic Hyperplasia (BPH) in men 1 . Dutasteride is poorly soluble; following oral administration the time to peak serum concentration of Dutasteride is 1 to 3 hrs.…”

Section: Introductionmentioning

confidence: 99%